La chaîne d'options affiche les données clés des options sur actions de aTyr Pharma à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour aTyr Pharma..

aTyr Pharma (NASDAQ:ATYR) Stock, Chaîne d'Options

ATYR PHARMA INC

aTyr Pharma

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

aTyr Pharma Inc

News

Legal

Press Releases

ROSEN, A LONGSTANDING LAW FIRM, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATYR

Penny Stocks

Deadline Approaching: aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of aTyr Pharma, Inc.(ATYR) Shareholders

Bragar Eagel & Squire, P.C. Reminds Investors of aTyr, Marex, Cepton, and MoonLake to Contact the Firm About their Rights in Filed Class Action Lawsuits

The Gross Law Firm Notifies Shareholders of aTyr Pharma, Inc.(ATYR) of a Class Action Lawsuit and an Upcoming Deadline

Shamis & Gentile, P.A. has Filed an Expanded Securities Class Action Lawsuit Against aTyr Pharma, Inc. (ATYR) and Alerts Investors of the December 8, 2025 Lead Plaintiff Deadline

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in aTyr Pharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATYR

ATYR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Deadline Alert: aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

Levi & Korsinsky Reminds aTyr Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 8, 2025 – ATYR

ATYR

CPTN

MLTX

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

Biomea Fusion

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

BeyondSpring

Connect Biopharma Holdings Limited - Ordinary Shares

Connect Biopharma Hldgs

Entera Bio

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

EXoZymes

InflaRx

Immix Biopharma

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Metagenomi

OKYO Pharma

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Pelthos Therapeutics

Quince Therapeutics

AVITA Medical

Repare Therapeutics

Sutro Biopharma

Shattuck Labs

Unicycive Therapeutics, Inc. - Common Stock

Comments

aTyr Pharma

aTyr Pharma (ATYR) Options

aTyr Pharma (NASDAQ:ATYR) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL